Innovation and Patent Law Reform: Hearings Before the Subcommittee on Courts, Civil Liberties, and the Administration of Justice of the Committee on the Judiciary, House of Representatives, Ninety-eighth Congress, Second Session, on H.R. 3285, H.R. 3286, and H.R. 3605 ... March 28, April 26, and June 6, 27, 1984, 2. daļaU.S. Government Printing Office, 1985 - 2897 lappuses |
No grāmatas satura
1.–5. rezultāts no 100.
950. lappuse
... regulatory delay . It is well - known that the impetus for patent term extension legislation came from the research intensive drug companies through the lobbying activities of the Pharmaceutical Manufacturers Association . PMA produced ...
... regulatory delay . It is well - known that the impetus for patent term extension legislation came from the research intensive drug companies through the lobbying activities of the Pharmaceutical Manufacturers Association . PMA produced ...
951. lappuse
... regulatory delays encountered by generic drug makers in bringing products to the market , the effective commercial monopoly life for the 50 top selling drugs turned out to be 15.5 years and for the 100 top selling drugs it was almost 14 ...
... regulatory delays encountered by generic drug makers in bringing products to the market , the effective commercial monopoly life for the 50 top selling drugs turned out to be 15.5 years and for the 100 top selling drugs it was almost 14 ...
953. lappuse
... regulatory review period are set forth above . 2 . The patent for which this extension is sought has never been ... Regulations , $ 1.56 ( a ) . I hereby declare that all statements made herein of my own knowledge are true and that all ...
... regulatory review period are set forth above . 2 . The patent for which this extension is sought has never been ... Regulations , $ 1.56 ( a ) . I hereby declare that all statements made herein of my own knowledge are true and that all ...
985. lappuse
... regulatory review for innovative drug products ; and ( 2 ) Accelerates the availability of safe and effective ... regulations for drugs approved before 1962 , the bill precludes FDA from requesting information from an ANDA applicant ...
... regulatory review for innovative drug products ; and ( 2 ) Accelerates the availability of safe and effective ... regulations for drugs approved before 1962 , the bill precludes FDA from requesting information from an ANDA applicant ...
1001. lappuse
... regulatory review period and the significant dates applicable to such activities . The Commissioner of Patents would be required to send a copy of the application containing the information to the Secretary who would be required within ...
... regulatory review period and the significant dates applicable to such activities . The Commissioner of Patents would be required to send a copy of the application containing the information to the Secretary who would be required within ...
Saturs
946 | |
977 | |
988 | |
1095 | |
1118 | |
1134 | |
1140 | |
1142 | |
1506 | |
1516 | |
1570 | |
1577 | |
1594 | |
1612 | |
1656 | |
1657 | |
1145 | |
1183 | |
1197 | |
1206 | |
1210 | |
1215 | |
1245 | |
1269 | |
1284 | |
1294 | |
1307 | |
1335 | |
1341 | |
1360 | |
1403 | |
1435 | |
1482 | |
1663 | |
1672 | |
1680 | |
1725 | |
1739 | |
1756 | |
1767 | |
1786 | |
1819 | |
1824 | |
1835 | |
1855 | |
1867 | |
1871 | |
1886 | |
1888 | |
1909 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
1962 Amendments 2d Cir Adkins agreement ANDA antitrust Appeals assignment available as prior Bass benefits beta blockers bill Bolar Circuit claims clinical testing commercial company/client compensation Congress Consent Judgment contract Corp corporation costs decision or settlement defendant Dextrose diazepam disclosed disclosure district court drug application electrolyte employed inventor employee estoppel federal filed firms grant Hoffmann-La Roche I.V. Solution industry Injection innovation invalid Kastenmeier Labs Lear doctrine legislation license licensee estoppel licensor litigation manufacture ment monopoly NAME TRADE NAME NCEs NDAS APPROVED patent application patent infringement patent issued patent law Patent Office patent protection patent rights patent system patent validity period pharmaceutical plaintiff preliminary injunction prior art prior invention question reduced to practice regulation relief result Roche royalties Sodium Sodium Chloride statute Supp supra note Tablet tion trade secret Trademark U.S. patent United United Kingdom Zenith
Populāri fragmenti
1551. lappuse - A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.
1573. lappuse - ... before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.
1510. lappuse - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
1191. lappuse - A patent shall be presumed valid. Each claim of a patent (whether in independent, dependent, or multiple dependent form) shall be presumed valid independently of the validity of other claims; dependent or multiple dependent claims shall be presumed valid even though dependent upon an invalid claim.
1485. lappuse - States, or (c) he has abandoned the invention, or (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States...
1330. lappuse - The several courts vested with jurisdiction of cases arising under the patent laws shall have power to grant injunctions according to the course and principles of courts of equity, to prevent the violation of any right secured by patent, on such terms as the court may deem reasonable...
1485. lappuse - ... b. the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or c.
1160. lappuse - In determining whether an accused device or composition infringes a valid patent, resort must be had in the first instance to the words of the claim. If accused matter falls clearly within the claim, infringement is made out and that is the end of it.
1153. lappuse - States, or (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent...
1465. lappuse - ... obligation to assign the application. All such individuals have a duty to disclose to the Office information they are aware of which is material to the examination of the application. Such information is material where there is a substantial likelihood that a reasonable examiner would consider it important in deciding whether to allow the application to issue as a patent.